Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Khaled Moussawi, MD, PhD (ucsf)
Headshot of Khaled Moussawi
Khaled Moussawi

Description

Summary

This study aims to examine the effects of Low-Intensity Focused Ultrasound (LIFU) on brain activity in patients with alcohol use disorder.

Details

This is a single-center, double-blind, controlled, randomized, complete block, 2-period crossover pilot trial. The study will assess target engagement of the ventral striatum after LIFU in patients with alcohol use disorder using resting state and task-based functional magnetic resonance imaging (fMRI).

Keywords

Alcohol Use Disorder, Substance Abuse Disorder, Alcohol, Alcoholism, Alcohol Drinking, Low Intensity Focused Ultrasound, VS LIFU/ VPL LIFU, VPL LIFU/VS LIFU

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Male or female ≥ 18 years of age.
  2. Documentation of an AUD diagnosis per DSM-5 criteria as evidenced by problematic pattern of alcohol use leading to clinically significant impairment or distress, as manifested by at least two of the DSM-5 criteria, occurring within a 12-month period.
  3. Be willing to undergo a brain MRI and follow study protocol.

You CAN'T join if...

  1. Pregnant or breastfeeding.
  2. Presence of a condition or abnormality that would compromise the safety of the patient or the quality of the data.
  3. Non-English speaking.
  4. Other investigational AUD treatments.
  5. Primary psychosis, Bipolar I, or severe personality disorder.
  6. Active suicidality or history of suicide attempt in the past 5 years.
  7. Cognitive impairment (MoCA <24)
  8. Significant medical or neurological disease, or life expectancy <12 mos.
  9. Significant brain abnormality on brain imaging.
  10. Any MRI exclusion criteria.

Location

  • University of California, San Francisco
    San Francisco California 94143 United States

Lead Scientist at University of California Health

  • Khaled Moussawi, MD, PhD (ucsf)
    The Translational Neuropsychiatry Through Neuromodulaton (TN²) laboratory investigates the neurobiology of substance use disorders and uses neuromodulation tools such as Low-Intensity Focused Ultrasound (LIFU), Transcranial Magnetic Stimulation (TMS), and Deep Brain Stimulation (DBS) to treat drug and alcohol addiction and related neuropsychiatric disorders.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT06518785
Study Type
Interventional
Participants
Expecting 25 study participants
Last Updated